Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
April 22, 2024 09:27 ET
|
Oculis Holding AG
Raised gross proceeds of $59 million through the issuance and sale of 5,000,000 of its ordinary shares to Icelandic institutional and existing investorsBecomes second company dual-listed on NASDAQ...
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
April 22, 2024 08:34 ET
|
Oculis Holding AG
Raised gross proceeds of $59 million through the issuance and sale of 5,000,000 of its ordinary shares to Icelandic institutional and existing investorsBecomes second company dual-listed on NASDAQ...
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
April 11, 2024 08:55 ET
|
Oculis Holding AG
$59 million financing includes participation from new Icelandic institutional and existing investors; Extends cash runway until 2H 2026 The Central Bank of Iceland, Financial Supervision has approved...
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
April 10, 2024 06:30 ET
|
Oculis Holding AG
Following significant strides made in advancing its late-stage pipeline with dual positive readouts in 2023 and a few more anticipated this year, Oculis further expands its executive leadership team...
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
April 08, 2024 06:30 ET
|
Oculis Holding AG
OCS-01 positive results in the first Phase 3 OPTIMIZE-1 trial were presented at the American Society of Cataract and Refractive Surgery (ASCRS) while topline readout from the second Phase 3 OPTIMIZE-2...
Oculis to Participate at Upcoming April Investor Conferences
April 04, 2024 06:30 ET
|
Oculis Holding AG
ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
March 18, 2024 06:30 ET
|
Oculis Holding AG
A successful year including NASDAQ listing and positive results from two Phase 3 programs in OCS-01: Phase 3 Stage 1 DIAMOND trial for Diabetic Macular Edema (DME), and Phase 3 OPTIMIZE-1 trial for...
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
February 28, 2024 06:30 ET
|
Oculis Holding AG
Completed enrollment in Phase 2b RELIEF trial of Licaminlimab (OCS-02), anti-TNF (tumor necrosis factor) alpha eye drops in Dry Eye Disease (DED); topline results expected in Q2 2024Second Phase 3...
Oculis to Present at Upcoming February Investor Conferences
January 29, 2024 06:30 ET
|
Oculis Holding AG
ZUG, Switzerland and BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
January 22, 2024 06:30 ET
|
Oculis Holding AG
ZUG, Switzerland, and BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or “the Company”), a global biopharmaceutical company purposefully driven to save sight and...